NasdaqCM:PIRS

Stock Analysis Report

Executive Summary

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States.

Snowflake

Fundamentals

Flawless balance sheet and slightly overvalued.

Risks

  • Pieris Pharmaceuticals has significant price volatility in the past 3 months.

Share Price & News

How has Pieris Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-2.9%

NasdaqCM:PIRS

-0.03%

US Biotechs

-1.0%

US Market


1 Year Return

-1.8%

NasdaqCM:PIRS

-8.1%

US Biotechs

-0.4%

US Market

PIRS outperformed the Biotechs industry which returned -8.1% over the past year.

PIRS underperformed the Market in United States of America which returned -0.4% over the past year.


Share holder returns

PIRSIndustryMarket
7 Day-2.9%-0.03%-1.0%
30 Day9.2%-0.1%-3.3%
90 Day37.4%3.1%0.8%
1 Year-1.8%-1.8%-7.3%-8.1%1.9%-0.4%
3 Year206.7%206.7%9.8%6.0%39.4%30.4%
5 Yearn/a8.1%3.1%54.2%37.1%

Price Volatility Vs. Market

How volatile is Pieris Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Pieris Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Pieris Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).

Pieris Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Pieris Pharmaceuticals is loss making, we can't compare its value to the US Biotechs industry average.

Pieris Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Pieris Pharmaceuticals, we can't assess if its growth is good value.


Price Based on Value of Assets

Pieris Pharmaceuticals is overvalued based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Pieris Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

-2.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Pieris Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.

Pieris Pharmaceuticals is not considered high growth as it is expected to be loss making for the next 1-3 years.

Pieris Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.

Unable to compare Pieris Pharmaceuticals's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Pieris Pharmaceuticals's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Pieris Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Pieris Pharmaceuticals performed over the past 5 years?

-19.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Pieris Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Pieris Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Pieris Pharmaceuticals's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Pieris Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Pieris Pharmaceuticals has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Pieris Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

  • Explore strong past performing companies in the pharmaceuticals & biotech industry.

Financial Health

How is Pieris Pharmaceuticals's financial position?


Financial Position Analysis

Pieris Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Pieris Pharmaceuticals's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Pieris Pharmaceuticals has no debt.

Pieris Pharmaceuticals currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Low level of unsold assets.

Pieris Pharmaceuticals has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Pieris Pharmaceuticals has sufficient cash runway for 1.9 years based on current free cash flow.

Pieris Pharmaceuticals has sufficient cash runway for 1.8 years if free cash flow continues to grow at historical rates of 25.2% each year.


Next Steps

Dividend

What is Pieris Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Pieris Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Pieris Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Pieris Pharmaceuticals has not reported any payouts.

Unable to verify if Pieris Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Pieris Pharmaceuticals has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Pieris Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

2.1yrs

Average management tenure


CEO

Steve Yoder (43yo)

4.7yrs

Tenure

US$2,621,008

Compensation

Mr. Stephen S. Yoder, also known as Steve, J.D., has been the Chief Executive Officer and President at Pieris Pharmaceuticals, Inc. since December 17, 2014. Mr. Yoder joined Pieris Pharmaceuticals GmbH as  ...


CEO Compensation Analysis

Steve's remuneration is higher than average for companies of similar size in United States of America.

Steve's compensation has increased whilst company is loss making.


Management Age and Tenure

2.1yrs

Average Tenure

44yo

Average Age

The tenure for the Pieris Pharmaceuticals management team is about average.


Board Age and Tenure

2.3yrs

Average Tenure

58yo

Average Age

The average tenure for the Pieris Pharmaceuticals board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellUS$3,753,51227 Sep 18
OrbiMed Advisors, L.L.C.
EntityCompany
Shares684,100
Max PriceUS$5.79
BuyUS$25,52517 Sep 18
Christopher Kiritsy
EntityIndividual
Role
Member of the Board of Directors
Shares5,000
Max PriceUS$5.11

Ownership Breakdown


Management Team

  • Claus Schalper

    Co-Founder & Senior Advisor

    • Tenure: 2.0yrs
  • Allan Reine (44yo)

    Senior VP

    • Tenure: 2.0yrs
    • Compensation: $871.26k
  • Steve Yoder (43yo)

    CEO, President & Director

    • Tenure: 4.7yrs
    • Compensation: $2.62m
  • Eckhard Niemeier

    VP & Head of Business Development

  • Christine Rothe

    Head of Discovery & Alliance Management and VP

  • Maria Kelman

    Director of Investor Relations

  • Shane Olwill

    Head of Development & Immuno-Oncology and VP

  • Ahmed Mousa

    VP, General Counsel & Corporate Secretary

    • Tenure: 2.3yrs
  • Frank Vollmering

    Vice President of Human Resources

    • Tenure: 1.6yrs
  • Louis Matis (68yo)

    Senior VP & Chief Development Officer

    • Tenure: 4.0yrs
    • Compensation: $1.12m

Board Members

  • Jim Geraghty (64yo)

    Chairman

    • Tenure: 1.7yrs
    • Compensation: $199.86k
  • Steve Yoder (43yo)

    CEO, President & Director

    • Tenure: 4.7yrs
    • Compensation: $2.62m
  • Ann Barbier (55yo)

    Director

    • Tenure: 1.3yrs
    • Compensation: $154.03k
  • Jean-Pierre Bizzari (65yo)

    Director

    • Tenure: 4.3yrs
    • Compensation: $139.95k
  • Chris Kiritsy (54yo)

    Director

    • Tenure: 2.9yrs
    • Compensation: $152.76k
  • Matt Sherman (63yo)

    Director

    • Tenure: 0.8yrs
    • Compensation: $99.96k
  • Maya Said (42yo)

    Director

  • Peter Kiener (67yo)

    Director

    • Tenure: 0.9yrs
    • Compensation: $105.52k
  • Michael Richman (58yo)

    Director

    • Tenure: 4.7yrs
    • Compensation: $144.40k

Company Information

Pieris Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Pieris Pharmaceuticals, Inc.
  • Ticker: PIRS
  • Exchange: NasdaqCM
  • Founded:
  • Industry: biotechnology
  • Sector: pharmaceuticals & biotech
  • Market Cap: US$246.964m
  • Shares outstanding: 49.39m
  • Website: Click here

Number of Employees


Location

  • Pieris Pharmaceuticals, Inc.
  • 255 State Street
  • 9th Floor
  • Boston
  • Massachusetts
  • 2109
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PIRSNasdaqCM (Nasdaq Capital Market)YesNew Common StockUSUSDDec 2014
PI6DB (Deutsche Boerse AG)YesNew Common StockDEEURDec 2014

Biography

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-w ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/18 00:36
End of Day Share Price2019/08/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.